Demand for Female Contraceptives Driving Growth in Women’s Health Market
VANCOUVER, Canada — The growing demand for female contraceptives is causing a surge in the women’s health care market, which is now expected to reach a value of $24.48 billion by 2027, a new report says.
The report, by Emergen Research, suggests the women’s health care market is experiencing a surge directly attributable to a growing demand for devices and drugs in applications comprising contraceptives, postmenopausal osteoporosis, hormonal infertility, menopause, endometriosis and polycystic ovary syndrome, among others.
The most-purchased devices included intrauterine devices, vaginal rings and implants; among the most sought after drugs are Prolia, Evista, Xgeva, Mirena and Zometa.
As outlined in the report, use of female contraception is beneficial in the prevention of health issues associated with pregnancy, particularly for pubescent girls, as well as in pregnancy planning to reduce the chances of infant mortality, which is higher in childbirths separated by a fewer number of years.
In addition, it provides various other prospective benefits including prolonged prospects for education and women empowerment, along with maintaining a healthy population and the economic growth of nations.
Increasing investments in femtech would give the players in the industry many growth opportunities, thus boosting the women’s health market over the forecast period.
Novel femtech such as wearables for recording and controlling the health of patients are likely to propel future demand in the women’s health market. Firms engaged in the production of mobile apps associated with menstruation and or fertility tracking include Clue, Glow, DOT, Eve and Cycles, among others.
A pdf sample of the report can be ordered here.